Kai Kisand

This inventor holds 9 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 5 EPO patents. Top assignee: Immunoqure Ag. Active years: 2016-2024.

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 66.7

CIPO Patents = 4

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 8.7

ph-index = 4

Forward Citations = 21(Granted Patents)

Company Filing History:

9 out of 9

Immunoqure Ag

patents

Years Active: 2016-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11945861 - Human anti-IFN-α antibodies (2024-04-02),

2. 10975144 - CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody (2021-04-13),

3. 10941198 - Human anti-IFN-α antibodies (2021-03-09),

4. 10875916 - Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F (2020-12-29),

5. 10131709 - Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 (2018-11-20),

6. 10112995 - Human anti-IFN-α antibodies (2018-10-30),

7. 10081676 - Human anti-IL-32 antibodies and methods of making and using the same (2018-09-25),

8. 9957319 - Method of isolating human antibodies (2018-05-01),

9. 9475872 - Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F (2016-10-25),

Title: The Innovative Contributions of Kai Kisand

Introduction

Kai Kisand is a prominent inventor based in Tartu, Estonia. He has made significant contributions to the field of biotechnology, particularly in the development of novel therapeutic antibodies. With a total of nine patents to his name, Kisand's work has the potential to impact various medical applications.

Latest Patents

Kisand's latest patents include groundbreaking advancements in human anti-IFN-α antibodies. These patents provide novel IFN-α binding molecules of human origin, specifically human-derived anti-IFN-α antibodies, along with their binding fragments, derivatives, and variants. Additionally, the patents describe pharmaceutical compositions, kits, and methods for use in diagnosis and therapy. Another significant patent involves CDNA encoding a monoclonal anti-IL-32 antibody, which also includes methods for the production of the antibody. This patent presents novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies, along with their binding fragments, derivatives, and variants, as well as pharmaceutical compositions, kits, and methods for diagnosis and therapy.

Career Highlights

Kisand is currently associated with Immunoqure AG, where he continues to push the boundaries of medical research and innovation. His work focuses on developing therapeutic solutions that can address critical health challenges.

Collaborations

Some of his notable coworkers include Adrian Hayday and Kai Krohn, who contribute to the collaborative environment that fosters innovation and research excellence.

Conclusion

Kai Kisand's contributions to biotechnology through his patents and collaborative efforts highlight his role as a leading inventor in the field. His work promises to advance therapeutic options and improve patient outcomes in various medical conditions.